Explore AstraZeneca's recent Form 6-K detailing CEO Pascal Soriot's transfer of 136,537 shares as a gift. Discover the implications for shareholder dynamics and regulatory compliance.
Explore AstraZeneca's Q3 2025 financial performance highlighting an 11% revenue growth, improved margins, and a strong pipeline. A must-read for investors!
Discover AstraZeneca PLC's latest 6-K report detailing voting rights, share capital, and compliance insights. Essential for investors and stakeholders in the biopharmaceutical sector.
AstraZeneca's 6-K filing details the approval of new articles of association, enhancing capital access. Key voting results and future trading updates included.
Discover AstraZeneca's latest Form 6-K report on Euan Ashley's director appointment at DexCom. Key insights on governance and compliance included.
AstraZeneca's Koselugo gains European approval for adults with NF1, showing 20% efficacy in trials. This marks a significant step in addressing rare disease treatment needs.
Discover AstraZeneca's latest financial report detailing Saphnelo's positive CHMP review for SLE treatment, trial insights, and future growth potential in autoimmune diseases.
Explore AstraZeneca's latest Form 6-K detailing Tezspire's FDA approval for CRSwNP, clinical trial successes, and market impact. Discover its potential in chronic respiratory care.
AstraZeneca's historic agreement with the U.S. government aims to lower drug prices by up to 80%. The deal includes a $50 billion investment in U.S. manufacturing and R&D, enhancing patient access.
Discover AstraZeneca PLC's latest financial insights, including voting rights and regulatory compliance under Form 20-F. Essential for investors and stakeholders.
Discover AstraZeneca's strategic shift in its listing structure, enhancing global investor access and compliance with UK governance. Key insights from the September 2025 Form 6-K.
Explore AstraZeneca PLC's latest 6-K report detailing a transaction by Non-Executive Director Karen Knudsen involving 9 ADSs. Key insights for September 2025 compliance.